Gazette – The Securities and Exchange Commission has charged Joseph F. Skowron III — a former Morgan Stanley manager of the six hedge funds that dumped large chunks of Human Genome Sciences stock after receiving insider tips about its drug trials in 2008 — with insider trading.
Showron, who managed funds affiliated with FrontPoint Partners, received information from Yves M. Benhamou, a member of the steering committee overseeing the Rockville biotech’s clinical trial of Albuferon for hepatitis C, according to the SEC complaint.
